Outlook: Organigram currently expects Q4 Fiscal 2023 net revenue to be higher than that of Q3 Fiscal 2023.
The Company expects to have adjusted gross margins increase in Q4, 2023, with cost savings initiatives realized, improved throughput from automation, and increased flower yields.
The Company expects to achieve positive Adjusted EBITDA in Q4 Fiscal 2023.
The company expects to resume generating positive Adjusted EBITDA, periods when the company achieves significant increases to sales will result in increases to receivables and this will negatively impact cash from operating activities.
The company forecasts a remaining cash capex spend of approximately C$10 million for Fiscal 2023 and if completed as planned during Fiscal 2023, the Company expects to generate positive free cash flows by the end of calendar 2023.
Image and article originally from seekingalpha.com. Read the original article here.